Sven Otto1, Karl Sotlar, Michael Ehrenfeld, Christoph Pautke. 1. Department of Oral and Maxillofacial Surgery, Ludwig-Maximilians-University, Lindwurmstraße 2a, 80337 Munich, Germany. Sven.Otto@med.uni-muenchen.de.
Abstract
INTRODUCTION: Osteonecrosis of the jaw is a serious side effect in patients receiving nitrogen-containing bisphosphonates intravenously due to malignant diseases. Albeit far less frequently, osteonecrosis of the jaw has also been reported to occur due to the oral administration of nitrogen-containing bisphosphonates due to osteoporosis. Annual infusions of zoledronic acid have been recommended in order to improve patient compliance, to optimize therapeutic effects and to minimize side effects. To date, osteonecrosis of the jaw has not been linked to the annual administration of bisphosphonates. CASE PRESENTATION: We report the case of a 65-year-old Caucasian woman suffering from osteoporosis who developed early stage osteonecrosis of the jaw in two locations, with chronic infections, after two months of oral bisphosphonate treatment and three annual administrations of zoledronic acid. Our patient was treated by fluorescence-guided resection of the necrotic jaw bone areas; local inflammation was treated by removal of a wisdom tooth and repeat root resections. Histopathology revealed typical hallmarks of osteonecrosis of the jaw. CONCLUSION: Osteonecrosis of the jaw may occur as a consequence of annual administrations of zoledronic acid. It is conceivable that, due to the pharmacological properties of bisphosphonates, a jaw bone that encounters frequent local inflammations is more likely to develop osteonecrosis.
INTRODUCTION:Osteonecrosis of the jaw is a serious side effect in patients receiving nitrogen-containing bisphosphonates intravenously due to malignant diseases. Albeit far less frequently, osteonecrosis of the jaw has also been reported to occur due to the oral administration of nitrogen-containing bisphosphonates due to osteoporosis. Annual infusions of zoledronic acid have been recommended in order to improve patient compliance, to optimize therapeutic effects and to minimize side effects. To date, osteonecrosis of the jaw has not been linked to the annual administration of bisphosphonates. CASE PRESENTATION: We report the case of a 65-year-old Caucasian woman suffering from osteoporosis who developed early stage osteonecrosis of the jaw in two locations, with chronic infections, after two months of oral bisphosphonate treatment and three annual administrations of zoledronic acid. Our patient was treated by fluorescence-guided resection of the necrotic jaw bone areas; local inflammation was treated by removal of a wisdom tooth and repeat root resections. Histopathology revealed typical hallmarks of osteonecrosis of the jaw. CONCLUSION:Osteonecrosis of the jaw may occur as a consequence of annual administrations of zoledronic acid. It is conceivable that, due to the pharmacological properties of bisphosphonates, a jaw bone that encounters frequent local inflammations is more likely to develop osteonecrosis.
Authors: Salvatore L Ruggiero; Thomas B Dodson; Leon A Assael; Regina Landesberg; Robert E Marx; Bhoomi Mehrotra Journal: J Oral Maxillofac Surg Date: 2009-05 Impact factor: 1.895
Authors: Sven Otto; Mario Hakim Abu-Id; Stefano Fedele; Patrick H Warnke; Stephan T Becker; Andreas Kolk; Thomas Mücke; Gerson Mast; Robert Köhnke; Elias Volkmer; Florian Haasters; Olivier Lieger; Tateyuki Iizuka; Stephen Porter; Giuseppina Campisi; Giuseppe Colella; Oliver Ploder; Andreas Neff; Jörg Wiltfang; Michael Ehrenfeld; Thomas Kreusch; Klaus-Dietrich Wolff; Stephen R Stürzenbaum; Matthias Schieker; Christoph Pautke Journal: J Craniomaxillofac Surg Date: 2010-07-02 Impact factor: 2.078
Authors: Sven Otto; Sigurd Hafner; Gerson Mast; Thomas Tischer; Elias Volkmer; Matthias Schieker; Stephen R Stürzenbaum; Emmo von Tresckow; Andreas Kolk; Michael Ehrenfeld; Christoph Pautke Journal: J Oral Maxillofac Surg Date: 2010-05 Impact factor: 1.895
Authors: Dennis M Black; Pierre D Delmas; Richard Eastell; Ian R Reid; Steven Boonen; Jane A Cauley; Felicia Cosman; Péter Lakatos; Ping Chung Leung; Zulema Man; Carlos Mautalen; Peter Mesenbrink; Huilin Hu; John Caminis; Karen Tong; Theresa Rosario-Jansen; Joel Krasnow; Trisha F Hue; Deborah Sellmeyer; Erik Fink Eriksen; Steven R Cummings Journal: N Engl J Med Date: 2007-05-03 Impact factor: 91.245
Authors: Joan C Lo; Felice S O'Ryan; Nancy P Gordon; Jingrong Yang; Rita L Hui; Daniel Martin; Matthew Hutchinson; Phenius V Lathon; Gabriela Sanchez; Paula Silver; Malini Chandra; Carolyn A McCloskey; Judy A Staffa; Mary Willy; Joe V Selby; Alan S Go Journal: J Oral Maxillofac Surg Date: 2009-09-24 Impact factor: 1.895
Authors: Christian Walter; Bilal Al-Nawas; Knut A Grötz; Christian Thomas; Joachim W Thüroff; Viktoria Zinser; Heinold Gamm; Joachim Beck; Wilfried Wagner Journal: Eur Urol Date: 2008-06-26 Impact factor: 20.096